Hims & Hers Shares Jump 7% After Lilly GLP-1 Prescription Expansion
Hims & Hers shares rose 7% after expanding its telehealth platform to allow prescriptions for Eli Lilly’s Zepbound vials, KwikPen, and Foundayo via LillyDirect with self-pay pricing options. This follows last month’s Novo Nordisk collaboration adding Wegovy access and underscores Hims’s push into GLP-1 weight loss therapies.
1. Expanded Lilly Partnership
Hims & Hers Health expanded its telehealth platform to enable licensed providers to prescribe Eli Lilly’s Zepbound vials, KwikPen, and Foundayo, fulfilled through LillyDirect pharmacy. The integration includes self-pay pricing options for customers, enhancing Hims’s ability to attract price-sensitive weight loss patients.
2. Broader GLP-1 Strategy
This new collaboration follows a partnership launched last month with Novo Nordisk for Wegovy injections and oral GLP-1 treatments. Together, these initiatives signal Hims’s strategic shift toward becoming a comprehensive provider of FDA-approved weight loss therapies.
3. Stock Market Reaction
Shares climbed 7% on the partnership news, reflecting investor optimism that expanded drug offerings and diversified supply channels will drive subscriber growth and revenue. The company’s focus on personalized treatment access and support services further underpins long-term growth prospects.